All In Biotech

NDA 217424 · Lnhc

Zelsuvmi

Berdazimer Sodium · Topical

Novel

CDER novel approval, Jan 5, 2024: To treat molluscum contagiosum

Last checked: Nov 19, 2026Latest source record: Jan 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jan 5, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

20

6 Phase 3, 0 recruiting

FAERS reports

95

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 8, 2025.

ZELSUVMI™ is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ZELSUVMI™ is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ( 1 )

Mechanism: ZELSUVMI is a nitric oxide releasing agent. The mechanism of action for the treatment of molluscum contagiosum is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 5, 2024 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • ZELSUVMI · BERDAZIMER SODIUM EQ 10.3% BASE · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Berdazimer" as an intervention, any sponsor and status, largest first.

All 20 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • application site pain46
  • application site erythema31
  • application site pruritus12
  • application site vesicles9
  • application site discolouration8
  • application site irritation8
  • application site rash8
  • application site exfoliation6
  • wrong technique in product usage process6
  • application site inflammation5
  • application site eczema4
  • application site scab4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202519
202676

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Lnhc

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.